公司资料
Inozyme 股价、新闻与催化剂
- 股票代码:
- INZY
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股价为何变动
Current closing-price context is not available for INZY.
公司概览
业务概览
Inozyme Pharma is a rare-disease company focused on tissue calcification and enzyme replacement biology. Its story centers on highly specialized pediatric and orphan indications.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Inozyme sits in specialty biotechnology.
商业模式特征
The business depends on clinical data, orphan-disease progress, and the ability to build value in a narrow rare-disease market.
生物医药行业定位
Inozyme is a rare-disease catalyst name whose stock reacts to proof-of-concept and regulatory steps.
未来催化剂
- Inozyme’s catalyst is INZ-701 in ENPP1 deficiency, plus any next-stage update that supports the mineralization-disease thesis. This remains a focused rare-disease story.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。